Didn’t have time to attend all the key sessions at ACR Convergence 2020? Listen to the experts as they present their views on the top abstracts for Still's disease.
A multicenter retrospective cohort study from Germany provides new evidence supporting the use of biologic disease-modifying antirheumatic drugs as first-line therapy in patients with adult-onset Still’s disease.
A multicenter retrospective cohort study from Germany provides new evidence supporting the use of biologic disease-modifying antirheumatic drugs as first-line therapy in patients with adult-onset Still’s disease.
Bone loss has been found to play a significant role in axial spondyloarthritis (axSpA) and regular assessments are recommended. How do you assess bone loss in your patients with axSpA?DXA scanTrabecular bone score Quantitative computed...
Bone loss has been found to play a significant role in axial spondyloarthritis (axSpA) and regular assessments are recommended. How do you assess bone loss in your patients with axSpA?DXA scanTrabecular bone score Quantitative computed...
Meta-regression showed a lower rate of incident cardiovascular disease in more recent data for patients with psoriatic arthritis, but not for patients with spondyloarthritis, researchers report.
Meta-regression showed a lower rate of incident cardiovascular disease in more recent data for patients with psoriatic arthritis, but not for patients with spondyloarthritis, researchers report.
In a cohort of patients with established rheumatoid arthritis being treated with first-line biologic or targeted synthetic DMARDs, 17% developed difficult-to-treat rheumatoid arthritis over 5 years.
In a cohort of patients with established rheumatoid arthritis being treated with first-line biologic or targeted synthetic DMARDs, 17% developed difficult-to-treat rheumatoid arthritis over 5 years.
A multicenter retrospective cohort study from Germany provides new evidence supporting the use of biologic disease-modifying antirheumatic drugs as first-line therapy in patients with adult-onset Still’s disease.
A multicenter retrospective cohort study from Germany provides new evidence supporting the use of biologic disease-modifying antirheumatic drugs as first-line therapy in patients with adult-onset Still’s disease.
Clinicians are encouraged to consider both inflammatory and non-inflammatory sources of pain and functional limitation in patients with PsA and MetS, and to tailor management accordingly.
Clinicians are encouraged to consider both inflammatory and non-inflammatory sources of pain and functional limitation in patients with PsA and MetS, and to tailor management accordingly.
